Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Key Points

• Rep. Gilbert Ray Cisneros Jr. disclosed a purchase of between $1,001 and $15,000 in Supernus Pharmaceuticals (NASDAQ:SUPN) on March 3, filed April 7, through his "150 MAIN STREET TRUST > BANK OF AMERICA" account.
• SUPN stock traded at $52.09 with a market cap of roughly $3.0 billion and a 1‑year range of $29.16–$59.68, while analysts hold an average rating of "Hold" and a consensus price target of $62.17.
• Insiders have been net sellers, including a VP sale of 50,000 shares (~$2.51M) and total insider sales of 120,881 shares (~$6.14M) over the last quarter, though insiders still own 8.8% of the company.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on March 3rd. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of MACOM Technology Solutions NASDAQ: MTSI on 3/27/2026.
• Purchased $1,001 - $15,000 in shares of StandardAero NYSE: SARO on 3/27/2026.
• Purchased $1,001 - $15,000 in shares of FirstService NASDAQ: FSV on 3/27/2026.
• Sold $1,001 - $15,000 in shares of Charles Schwab NYSE: SCHW on 3/27/2026.
• Sold $1,001 - $15,000 in shares of Advanced Energy Industries NASDAQ: AEIS on 3/27/2026.
• Sold $1,001 - $15,000 in shares of Flex NASDAQ: FLEX on 3/27/2026.
• Purchased $1,001 - $15,000 in shares of LPL Financial NASDAQ: LPLA on 3/27/2026.
• Purchased $1,001 - $15,000 in shares of DoorDash NASDAQ: DASH on 3/27/2026.
• Sold $1,001 - $15,000 in shares of Viavi Solutions NASDAQ: VIAV on 3/27/2026.
• Purchased $15,001 - $50,000 in shares of Fabrinet NYSE: FN on 3/27/2026.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock traded up $0.48 on Thursday, reaching $52.09. The stock had a trading volume of 92,294 shares, compared to its average volume of 718,922. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $59.68. The stock has a market cap of $3.00 billion, a P/E ratio of -76.60, a price-to-earnings-growth ratio of 1.57 and a beta of 0.73. The company has a 50 day simple moving average of $51.24 and a 200 day simple moving average of $49.67.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Hantz Financial Services Inc. lifted its position in shares of Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company's stock valued at $30,000 after buying an additional 281 shares in the last quarter. Rockefeller Capital Management L.P. increased its holdings in Supernus Pharmaceuticals by 354.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company's stock worth $42,000 after acquiring an additional 660 shares in the last quarter. Torren Management LLC bought a new stake in Supernus Pharmaceuticals during the 4th quarter worth approximately $49,000. USA Financial Formulas purchased a new position in Supernus Pharmaceuticals during the third quarter valued at approximately $50,000. Finally, EverSource Wealth Advisors LLC purchased a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $51,000.

Insiders Place Their Bets

In other news, Director Bethany Sensenig sold 4,475 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $51.01, for a total value of $228,269.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 50,000 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $50.28, for a total value of $2,514,000.00. Following the sale, the vice president owned 17,044 shares of the company's stock, valued at $856,972.32. This represents a 74.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 120,881 shares of company stock valued at $6,139,356. Insiders own 8.80% of the company's stock.

Wall Street Analyst Weigh In

SUPN has been the topic of several research reports. Stifel Nicolaus raised their target price on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a "hold" rating in a research report on Friday, December 19th. Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Zacks Research cut shares of Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Thursday, January 29th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Sunday, March 8th. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $62.17.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.